Immunomedics (NASDAQ:IMMU), halted today as news broke that the FDA gave approval to its treatment for triple-negative breast cancer patients, jumped after resuming trading after hours.
The shares ended the postmarket session up 29.2% on heavy volume.
The $28.38 quoted after hours would mark a 20-year high for the stock, which last crossed the $25/share threshold in March 2000.
https://seekingalpha.com/news/3563425-immunomedics-up-29-in-postmarket-resumption
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.